Syngene International Reports FY26 Results: Revenue Up, Profits Down

Syngene International reported its full-year FY26 revenue from operations grew 3% to ₹3,739 Cr, up from ₹3,642 Cr in FY25. Revenue for the fourth quarter also increased by 2% year-on-year to ₹1,037 Cr.

Despite revenue gains, profitability declined. For the full year, Profit After Tax (PAT) before exceptional items dropped 20% to ₹380 Cr compared to ₹475 Cr in FY25. The fourth quarter saw PAT before exceptional items fall 16% to ₹153 Cr, down from ₹183 Cr in Q4 FY25.

Operating EBITDA margins also saw a significant contraction, falling to 25% in FY26 from 29% in FY25. In the fourth quarter, margins declined to 29% from 34% in the prior year's quarter.

Key Financial Takeaways

The results highlight a contrast: Syngene successfully expanded its top line, indicating continued client demand for its services. However, profitability is pressured by contracting margins and increased operating costs.

This suggests that while demand for Syngene's services remains strong, the company faces challenges in converting revenue into profit. This could stem from ongoing investments in new facilities and other operational expenses.

The Board recommended a final dividend of ₹1.25 per share for FY26, subject to shareholder approval.

About Syngene International

Syngene International, established in 1993, is a leading contract research, development, and manufacturing organisation (CRDMO) based in Bengaluru. It provides integrated scientific services across pharmaceuticals, biotechnology, nutrition, and other sectors. Founded by Kiran Mazumdar-Shaw, it has evolved from a contract research organisation (CRO) into a comprehensive CRDMO for small and large molecules.

In the previous fiscal year, FY25, the company reported revenue of ₹3,642 Cr and PAT of ₹475 Cr, with EBITDA margins around 30%. Syngene has also been expanding its global footprint, including the acquisition of its first US manufacturing facility for biologics.

Recent Developments & Future Outlook

Syngene is actively expanding its capabilities in Antibody-Drug Conjugates (ADC) and has commenced operations at its new ADC discovery laboratory. The company has also achieved Good Clinical Practice - National Accreditation Board for Testing and Calibration Laboratories (GCP-NABL) accreditation.

Its commitment to sustainability was recognised with its inclusion in the S&P Global Sustainability Yearbook 2026 and as an 'Industry Mover' for ESG improvements. Continued investments in new biologics manufacturing facilities are underway, expected to drive future growth but also contribute to near-term costs.

Profitability Concerns & Risks

Profitability pressure remains a key concern, evidenced by the 20% year-on-year decline in PAT for FY26 and significant contraction in operating EBITDA margins (FY26: 25% vs 29% in FY25; Q4 FY26: 29% vs 34% in Q4 FY25).

Additional operating costs are anticipated as the company brings its new biologics manufacturing facility in India into operation, which could further impact margins in the short term. Syngene's performance can be significantly impacted by a single large-molecule biologics client, indicating potential client concentration risk.

Competitive Landscape

Syngene operates in a competitive landscape alongside global players like WuXi AppTec and Charles River Laboratories, as well as domestic firms such as Sai Life Sciences. WuXi AppTec is known for its extensive capabilities and strategic 'follow and win the molecule' approach. Charles River Laboratories operates on a larger revenue scale.

These peers are also investing heavily in expanding capacity and capabilities, highlighting the dynamic nature of the contract research and manufacturing sector.

Investor Focus Areas

Investors will be closely watching the performance and cost implications of the new biologics manufacturing facility once it is fully operational. Details and future outlook from the investor earnings call on April 30, 2026, will be crucial for assessing management's strategy and guidance. Progress on new business lines, especially in Antibody-Drug Conjugates (ADC), and the conversion of pilot programs into larger contracts will be key. The impact of upcoming leadership transitions, with the CEO stepping down on June 30, 2026, will also be a focus.